journal article·2023-02-08

Fluorescence Imaging-Incorporated Transcriptome Study of Glutathione Depletion-Enhanced Ferroptosis Therapy via Targeting Gold Nanoclusters

Dan Zhao, Xiaoyu Huang, Yanan Tian, Jianhua Zou, Fu Wang, Xiaoyuan Chen

Publisher page

Abstract

Ferroptosis plays an important role in tumor inhibition and is a new type of programmed cell death. Recent studies have shown that glutathione (GSH) depletion is an effective method to enhance the therapeutic efficacy of ferroptosis; however, a systematic investigation of the phenomenon is limited. Herein, we provide a facile fluorescence imaging-incorporated transcriptome strategy to visualize the process and explore the mechanism of GSH depletion-enhanced ferroptosis. The proposed multifunctional nanoplatform is achieved using simple transferrin receptor aptamer-functionalized fluorescent gold nanoclusters (termed TfRA-AuNCs), which exhibit efficient hydroxyl radical generation and GSH-depleting capabilities. Live cell fluorescence imaging results revealed that TfRA-AuNCs were endocytosed into 4T1 cells and were mostly distributed in lysosomes. In vitro results indicated that TfRA-AuNCs enhanced the ferroptosis effect in 4T1 cells. Importantly, transcriptome analysis indicated that 4T1 cells treated with TfRA-AuNCs regulated the expression change of ferroptosis-related genes, and the Kyoto Encyclopedia of Genes and Genomes pathway identified the GSH metabolism pathway involved in ferroptosis, thus revealing the exact molecular mechanism of ferroptosis induced by TfRA-AuNCs at the RNA level. Furthermore, in vivo results confirmed the tumor inhibition effect, tumor-targeted fluorescence imaging, and long-term biocompatibility after TfRA-AuNC treatment. This study introduces a new possibility for the mechanistic study of nanoagent-induced ferroptosis in tumor treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanocluster Synthesis and Applications · Ferroptosis and cancer prognosis · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Environmental Science and Engineering, State Environmental Protection Key Laboratory of Environmental Health Impact Assessment of Emerging Contaminants, Shanghai Jiao Tong University, Shanghai 200240, P. R. China

Med-X Research Institute and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, P. R. China

Departments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore 117597, Singapore

Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore

Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore

Funding

Shenzhen Science and Technology Innovation Commission · National Natural Science Foundation of China · Guangdong Provincial Key Laboratory of Biomedical Optical Imaging · Shenzhen Science and Technology Program

References (72)

Show source-provided references
1. 10.1038/s41419-020-2298-210.1038/s41419-020-2298-2 ↗
2. 10.1038/s41568-022-00459-010.1038/s41568-022-00459-0 ↗
3. 10.1002/adma.20190419710.1002/adma.201904197 ↗
4. 10.1002/adma.20170400710.1002/adma.201704007 ↗
5. 10.1039/D1BM00721A10.1039/D1BM00721A ↗
6. 10.7150/thno.6548010.7150/thno.65480 ↗
7. 10.1021/jacs.1c0747110.1021/jacs.1c07471 ↗
8. 10.1016/j.ymthe.2021.03.02210.1016/j.ymthe.2021.03.022 ↗
9. 10.1016/j.biomaterials.2021.12111010.1016/j.biomaterials.2021.121110 ↗
10. 10.1002/anie.20201485210.1002/anie.202014852 ↗
11. 10.1016/j.biomaterials.2020.11991110.1016/j.biomaterials.2020.119911 ↗
12. 10.1002/smll.20210204610.1002/smll.202102046 ↗
13. 10.1038/nrg248410.1038/nrg2484 ↗
14. 10.1002/adma.20210677310.1002/adma.202106773 ↗
15. 10.1002/smll.20190461910.1002/smll.201904619 ↗
16. 10.15252/emmm.20211435110.15252/emmm.202114351 ↗
17. 10.1155/2020/346984010.1155/2020/3469840 ↗
18. 10.1016/j.redox.2021.10194910.1016/j.redox.2021.101949 ↗
19. 10.1002/smll.20200135610.1002/smll.202001356 ↗
20. 10.1021/acsnano.1c0810810.1021/acsnano.1c08108 ↗
21. 10.1002/smll.20200125110.1002/smll.202001251 ↗
22. 10.1021/acsnano.8b0639910.1021/acsnano.8b06399 ↗
23. 10.1016/j.apsb.2018.03.01010.1016/j.apsb.2018.03.010 ↗
24. 10.1073/pnas.97.22.1227810.1073/pnas.97.22.12278 ↗
25. 10.1002/smtd.20200106610.1002/smtd.202001066 ↗
26. 10.1021/acsnano.9b0778910.1021/acsnano.9b07789 ↗
27. 10.1002/smll.20200170410.1002/smll.202001704 ↗
28. 10.1002/smll.20210226910.1002/smll.202102269 ↗
29. 10.1016/j.ijpharm.2021.12093710.1016/j.ijpharm.2021.120937 ↗
30. 10.3762/bjnano.11.4210.3762/bjnano.11.42 ↗
31. 10.1021/acsami.1c1427510.1021/acsami.1c14275 ↗
32. 10.1039/C5NR01284H10.1039/C5NR01284H ↗
33. 10.1002/anie.20201601410.1002/anie.202016014 ↗
34. 10.1016/j.talanta.2019.12034210.1016/j.talanta.2019.120342 ↗
35. 10.1021/acs.analchem.8b0088510.1021/acs.analchem.8b00885 ↗
36. 10.1021/acsami.8b0020710.1021/acsami.8b00207 ↗
37. 10.3390/ijms2216892310.3390/ijms22168923 ↗
38. 10.1021/jacs.9b1149010.1021/jacs.9b11490 ↗
39. 10.1089/nat.2015.058510.1089/nat.2015.0585 ↗
40. 10.1021/acs.chemmater.6b0514110.1021/acs.chemmater.6b05141 ↗
41. 10.1021/acs.analchem.9b0362910.1021/acs.analchem.9b03629 ↗
42. 10.1039/D1AN01003D10.1039/D1AN01003D ↗
43. 10.3389/fchem.2020.0021910.3389/fchem.2020.00219 ↗
44. 10.1016/j.saa.2020.11931610.1016/j.saa.2020.119316 ↗
45. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
46. 10.1016/j.critrevonc.2022.10373210.1016/j.critrevonc.2022.103732 ↗
47. 10.1016/j.cell.2017.09.02110.1016/j.cell.2017.09.021 ↗
48. 10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
49. 10.3389/fphar.2017.0099210.3389/fphar.2017.00992 ↗
50. 10.1002/smtd.20210084810.1002/smtd.202100848 ↗
51. 10.1016/j.freeradbiomed.2018.09.04310.1016/j.freeradbiomed.2018.09.043 ↗
52. 10.3389/fnins.2021.66166310.3389/fnins.2021.661663 ↗
53. 10.1007/s10571-021-01092-510.1007/s10571-021-01092-5 ↗
54. 10.1016/j.tcb.2020.02.00910.1016/j.tcb.2020.02.009 ↗
55. 10.1155/2022/491472710.1155/2022/4914727 ↗
56. 10.1074/jbc.RA119.00954810.1074/jbc.RA119.009548 ↗
57. 10.18632/oncotarget.516210.18632/oncotarget.5162 ↗
58. 10.1039/C0CS00018C10.1039/C0CS00018C ↗
59. 10.1038/s41565-019-0527-610.1038/s41565-019-0527-6 ↗
60. 10.1126/sciadv.abj883310.1126/sciadv.abj8833 ↗
61. 10.1021/acsnano.1c0846410.1021/acsnano.1c08464 ↗
62. 10.1021/es061780010.1021/es0617800 ↗
63. 10.1016/0003-2697(86)90061-810.1016/0003-2697(86)90061-8 ↗
64. 10.1101/pdb.prot09550510.1101/pdb.prot095505 ↗
65. Chan L. L. Y. · 2017 · 1601 · 2710.1007/978-1-4939-6960-9_3 ↗
66. 10.1021/acsami.7b1516510.1021/acsami.7b15165 ↗
67. 10.1016/j.anireprosci.2010.05.00510.1016/j.anireprosci.2010.05.005 ↗
68. 10.1016/S0091-679X(08)61717-310.1016/S0091-679X(08)61717-3 ↗
69. Martinez A. M. · 2020 · 2108 · 12510.1007/978-1-0716-0247-8_11 ↗
70. 10.1016/j.tiv.2013.01.01610.1016/j.tiv.2013.01.016 ↗
71. Sugimoto W. · 2021 · 2274 · 20710.1007/978-1-0716-1258-3_18 ↗
72. 10.1186/gb-2002-3-7-research003410.1186/gb-2002-3-7-research0034 ↗